Connect with us

Cannabis News

Coca Prohibition Is More Harmful Than The Plant Itself, World Health Organization Review Concludes

Published

8 months ago

on

“Research records, however, documents strongly documented public health damage related to position strategies in all scales”.

Mattha Busby, filter

The consumption of coca-leaf during the Andes does not have a significant risk, but the official CCO control strategies are linked according to a review of “Public Health Damage”.

Filter It was a previous copy of the report distribute Expert Commission on Drug Addiction (ECDD).

Coca, a stimulating and medicinal component of the cocaine component, banned by UN 1964 His researchers claimed Chewing the coca leaf is “definitively harmful” and “cause of racial degeneration of many population groups.” A who is also the paper as well describe Using a rich calcium plant “as a social disease”.

Despite the production of location leaves, during decades, Peru, Bolivia and Ecuador, during the drug war, indigenous communities remain in deep spiritual values ​​- in the height of all time in Colombia.

“Reviewed research for this report does not reveal evidence caused by the damage to public health related to coca leaves” to states ECDD’s extensive scientific review of commissioned. “Research records, however, documents strongly documented public health damage related to position strategies in all scales”.

The review is currently in draft mode and is subject to copying. It was commissioned among the growing international citation Koke, to finish the prohibition of Coca Filter previously reported.

In October, an international group of independent experts contracted by ECDD, and should be taken into account the most limited situation to change in the Coca’s current program. The meaning is that researchers understand the sources of leaves that understand the impossible.

One of the recommendations would be presented in December to the Narkotic Drug Commission, with a rotating member of 53 National Member States. In March 2026, the CND will vote for any recommendation. Coca may change or disable, which would have great ramifications, finish his use of criminalization and potentially providing an important economic economy in Latin American producers.

“We haven’t been a recommendation for the Commission, but it will be difficult to recommend how they could recommend KOKA Calendar,” Steve Rolls, Transform Drug Policy Foundation, charity campaign, drug legal regulation Filter.

“It’s quite likely to recommend (ECDD) really desecute, that is, they expect a lot of people in Colombia, Bolivia and civil society,” he continued. “Leaving the Coca in any schedule does not implicitly criminalizes millions of people who use it traditionally.”

However, those who make a scholarship recommendation, Rolles expects the CND currently The United Kingdom, Saudi Arabia and China counts among members, to vote. “The banners would be around forbiders and any desecrants would be forbidden because they were so paranoids around the cocaine,” he said.

In February, President Colombia gave the President Gustavo Petro Legalization of cocaine, described “worse than whiskey”. The external government of Bolivia’s left and indigenous government is called “Coca leaf colonization”, “but it will not be very difficult that the right government will put reform.

Whosely-based pesticides based on the rounded papers showed exposure, with a safe carcinogene, the number of medical consultations in the coke crop crop is “increased by the number of medical communities and breathing.”

He added that another study was eligible to increase coca farmers with increasing production of production, “increasing the exposure to the subsequent coca-plots” increasing exposure to chemicals. “

In the 1990s Coca farmers destroyed their crops and even when they were arrested and prosecuted for traditional uses. “Chronic exposure to agro-chemical products increases health risks related to neurological damage, bodies failure and reproductive health problems,” the papers said. “Pesticides and other farmers worked in the planned crop can cause security profiles and health profiles and health risks related to the use of the workshop.”

Indigenous spilled areas also complained “Flu symptoms, including nausea, dizziness, intervals, diarrhea, depending on the 2001 Report of the 2001 Institute”, according to the 2001 Republic of the Institute, Progressive thought.

“At least it seems that the discussion will encourage science and evidence,” Ricardo Sobern, Devida, the former president of the official drug control committee, said, said Filter. “Latin American states, as well as 53 members of CND, I must understand that the desktop will strengthen the gang fighting.”

The director of the Martin Jelsma, the Transnational Institute, said the review report “clearly” establishes that there is no harm or dependency of public health related to Coca leaf. “In terms of use of medicines, the evidence is still preliminary, but the potential is” great interest “to establish efficiency and safety for future development in human medicine”, ” Filter. “These basic consequences remove the original justification at the I.

The only reason to keep the coca leaf will remain in cocaine cocaine, “and the report indicated that the cocaine can be created from the Coca leaf” solvent extraction “than the process of” conversion “that assumes the chemical transformation of the molecule.”

The report refers to Koka’s cultural meaning, as well as the use of herbal medicine, but the violation of indigenous and human rights rights “intentionally avoided the impact of current controls,” he said.

The revision does not have the result of the healthcare consequences of the enforcement strategy of eradication of coca and eradicate traffic supply, Many experts say fuel violence.

Composing issues created as a result of prohibition by Coca, conservation campaigns said to eradicate the efforts that often comply with the growers to be further from the inspections of law enforcement.

The report is to use food in Coca, drinks such as energy tonic and beer, they are also increasing cosmetics that claim anti-aging properties and fabrics.

Although the report is noticed by public health damage associated with the leaf, the report has said “Undercoming literature on botanical, historical and cultural leaves, which evaluate their clinical effects are properly designed.” However, he said, “There is no evidence … a serious coca-leaf of humans.”

This article was originally published FilterUse of drug use, drug policy and human rights to reduce the damage to the online magazine through a lens. Continue filter Blues, X or Ocuookand Sign up for his newsletter.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Related Topics:
Continue Reading

Cannabis News

Cannabis operators report mixed results as rescheduling reshapes the financial outlook

Published

14 hours ago

on

May 14, 2026

By

The rescheduling came mid-quarter and rewrote the tax math for each medical sales operator, but the underlying revenue picture remained uneven in early 2026, with acquisitions driven at one end of the scale and continued top-line compression at the other.

Vireo Growth: Back on $106 million deal
Vireo Growth Inc. reported Q1 GAAP revenue of $106.2 million, up 333.5% year-over-year, driven almost entirely by recent acquisitions rather than organic growth. The company completed the Schwazze acquisition in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. At the end of the quarter, it closed Eaze and Hawthorne Gardening, FLUENT Corp. announced an acquisition agreement and executed a California dispensary joint venture with Glass House Brands. Treating all acquisitions as closed on January 1, 2025 on a pro forma basis, revenue was $210.2 million and adjusted EBITDA was $42.2 million. The company ended the quarter with $137.8 million in cash.

John Mazarakis, CEO of Vireo, said: “Performance in the first quarter met our expectations and we are excited to welcome Schwazze, Eaze and Hawthorne to Vireo. We are focused on integration and optimization across the platform, while remaining opportunistic regarding growth opportunities associated with further acquisitions.”

Cresco Labs: $151 million, 280E relief and Texas license
Cresco Labs reported Q1 revenue of $151 million, down from $165.8 million in Q1 2025. Adjusted gross margin was 50.7% and adjusted EBITDA margin of $33 million was 21.7%. Cash at the end of the quarter was $67 million against a $310 million secured term loan. The company was conditionally granted a Texas Compassionate Use Program license after the quarter ended and opened two new dispensaries in Ohio.

Management said, “Moving the state’s legal medical cannabis from Schedule I to Schedule III is the most impactful reform this industry has seen, and it validates the work we’ve been executing for years. We’ve built the operational foundation and balance sheet discipline to reap the immediate benefits of rescheduling, and position Cresco to take advantage of the broader path to normalization.”

Jushi Holdings: 4% growth, 460 basis point margin expansion
Jushi Holdings reported first-quarter revenue of $66.4 million, up 4% year-over-year, with gross profit margin up 460 basis points to 45%. Adjusted EBITDA was $11.4 million, up 17.2%. The margin improvement was driven by higher production volumes in Ohio, Massachusetts and Pennsylvania and the performance of grower processors. Jushi brand products accounted for 58% of retail revenue in vertical markets. The company refinanced $132.3 million in debt during the quarter, providing $160 million in new debt through 2029.

Jim Cacioppo, president and CEO, said: “The recent scheduling of state-licensed medical marijuana for Schedule III is an important milestone for the industry, eliminating 280E tax limitations for medical operations and supporting a more favorable long-term operating environment.” Medical sales accounted for about 60% of Jushi’s 2025 revenue, making this material relief.

iAnthus Capital: Revenue falls to $33.5 million
iAnthus Capital reported first-quarter revenue of $33.5 million, down $4.6 million from 2025’s first quarter. Gross margin was 47.5%, up 477 basis points from the 2025 quarter. The company did not provide a management comment in the press release.

Country farms: international export record, fourth consecutive quarter of net income
Village Farms International reported first quarter consolidated net sales of $50.2 million, up 27% year-over-year, with net income of $2.9 million and adjusted EBITDA of $9.9 million, up 118% year-over-year. International export sales increased 171% to a record $14.6 million, driven by demand for EU-GMP compliant products in Germany. Pure Sunfarms had the top Canadian market share in dried flowers for the 15th consecutive month. The company started planting the first half of its Delta 2 greenhouse expansion and expects its Phase II facility in the Netherlands to reach full capacity by the end of 2026, which would quadruple Dutch production.

Michael DeGiglio, President and CEO, said: “Our first quarter results reflect a strong start to the year and continued momentum in our largest markets, with adjusted EBITDA growth of 118% year-over-year, significantly outpacing revenue growth of 27%, driven by our international business and continued leadership in Canada.

Cronos Group: Record revenue, $822 million in cash
Cronos Group reported Q1 net income of $45.2 million, up 40% year-over-year and a record quarter, with net income of $15.7 million and adjusted EBITDA of $5.1 million. Israel led growth PEACE NATURALS grew 53% for ninth consecutive record quarter. In Canada, the Spinach brand took first place in vapes with a 9.8% share of the national market, and maintained its top spot in edibles at 20.8%. The company ended the quarter with $821.9 million in cash and authorized a new $50 million stock repurchase program. The deadline to close the acquisition of CanAdelaar, one of the ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, has been extended to September 9, 2026 to allow time for regulatory approvals.

Mike Gorenstein, chairman, president and CEO, said, “Cronos achieved net earnings and gross profit in the first quarter as we continue to execute against our unlimited product strategy and the additional supply from Cronos GrowCo’s expansion fuels the next phase of our growth.”

Org chart: Revenue down 9%, Sanity Group acquisition closes after quarter
Organigram Global reported fiscal second quarter net income of $59.8 million, down 9% year-over-year, with adjusted EBITDA of $0.9 million, down 82%. Lower vape and pre-infusion sales drove the decline, along with a $5.8 billion dent in the U.S. hemp business. The company achieved a record quarterly harvest of over 32,000kg at its Moncton facility, up 56% year-on-year, and launched 10 SKUs in Australia targeting over 4,000 pharmacies. At the end of the quarter, Organigram acquired Sanity Group, one of Germany’s leading cannabis companies, and updated its 2026 guidance to net revenue of more than $350 million.

James Yamanaka, CEO, said: “Q2 reflected our poor performance in vaporizers and temporary challenges in pre-infusion production, compounded by slower industry growth. We have acted quickly to address these issues, and the operational changes and product improvements we have implemented are already beginning to stabilize performance.”

Greg Guyatt, Chief Financial Officer, said: “The financial impact of the competitive and operational challenges encountered earlier in fiscal 2026 is believed to have materialized in the first half of the year, and we are now beginning to stabilize performance. We expect to resume a trajectory of margin expansion and improved profitability during the second half of the year, supported by positive revenue and international sales growth. The Sanity Group.”

Continue Reading

Cannabis News

Medical Marijuana Helps Pain Patients Reduce Use Of Opioids, New Study Shows

Published

14 hours ago

on

May 14, 2026

By

As opioids continue to cause overdose deaths, a new study suggests that making medical cannabis available and affordable could help patients reduce their use of prescription painkillers.

“Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm reduction tool for some patients seeking to reduce their reliance on higher-risk opioid medications,” researchers at the University of Pennsylvania Perelman School of Medicine found.

The study, a prospective observational trial at the Hospital of the University of Pennsylvania, followed 29 adults over five months. All had been living with chronic pain for years—an average of 11 years—and were already taking opioid medications, but struggled to taper off of them despite other treatments.

The study is unique in its focus on cost as a factor in access to medical marijuana, with the researchers describing their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

Participants were recruited from a university outpatient chronic pain clinic and then completed monthly pain assessments using the Numeric Pain Rating Scale (NRS). The researchers measured daily opioid use, measured in milligrams of morphine equivalents (MME).

“Seven patients (24%) were able to completely discontinue opioid therapy at the end of the study, five of whom did so by the second month. Pain levels also decreased over time,” the authors wrote.

Notably, “there was a statistically significant reduction in mean pain scores experienced over the five-month study period,” says the paper published in the Cureus Journal of Medical Science.

“There was also a reduction in average opioid consumption of about 32 MME per day, which remained the same throughout the follow-up. In addition, seven patients were able to completely discontinue opioid therapy during the study.”

“Mean daily opioid consumption decreased from 46.8 MME/day at baseline to 16.2 MME/day at one month and remained low during the five-month follow-up period,” the researchers found.

What set the new study apart was not just the inclusion of medical cannabis, but the deliberate removal of cost as a barrier. Participants “consistently identified cost as a major barrier to initiating medical cannabis” before enrolling in the study, the document says.

Noting the novelty of the study, they added their hypothesis: “Improving access to medical cannabis will allow a subset of patients, especially those with a high cost barrier, to reduce or discontinue opioid use while maintaining adequate pain control.”

“These results suggest that medical cannabis may be a useful adjunctive therapy to reduce opioid use, relieve chronic pain, and improve health-related quality of life,” they concluded.

“The findings of this study add to the body of literature supporting the safety profile and potential therapeutic role of cannabis.”

The studies the authors are cautious in their conclusions, warning of limitations and the need for further research. “The sample size was small and derived from a single clinical site, and there was no control group.” And because “patients self-titrate cannabis products, leading to variability in dosage and frequency of use,” the findings are not standardized.

But the authors concluded that “when used under appropriate medical supervision, medical cannabis may be an effective adjunctive strategy to reduce opioid use among patients receiving long-term opioid therapy.”

This study follows a Recent research shows that using medical marijuana helps people reduce their use of other drugs, including opioids.sleep aids and antidepressants. They also experience fewer negative side effects after switching from prescription drugs to cannabis, according to a study involving more than 3,500 patients.

It also comes from behind President Donald Trump says marijuana ‘can make people feel a lot better’ and serves as a “substitute for addictive and potentially lethal opioids.”

Last month, the Trump administration announced it moving forward with federal reclassification of marijuana medicinal cannabis is classified under Schedule I to III of the Controlled Substances Act.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Livermore Falls debates cannabis licensing fees

Published

2 days ago

on

May 13, 2026

By











Existing medical cannabis licensing fees will be temporarily applied to recreational marijuana businesses, the Select Committee decided on May 5. Board members agreed 4-1 to the temporary change, as long as officials say the fees are higher than necessary and accurately reflect the town’s oversight costs.

Bryce Cobb, Livermore Falls’ code enforcement officer, plumbing inspector, health officer and E-911 dispatcher, said voters approved the amended cannabis ordinance on April 28. Cobb said the amended ordinance allows recreational marijuana businesses and the next step was to establish a fee schedule. Recreational cannabis businesses operating in town would require local licensing approval under the ordinance.

Asked if he had fee schedules from other towns to compare, Cobb said he did not. Additionally, the town’s fee schedule specifically mentions medicinal cannabis.

“So it could be medical and adult use,” Cobb said when discussing whether the existing fee structure could apply to recreational businesses.

Read more at Sun Magazine










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media